39 pharmaceutical companies to disclose first-half results report, more than 40% of the pre-happy

"
Pharmaceutical Network Industry Dynamic" According to The Minnet data, as of June 5, a total of 39 pharmaceutical companies disclosed the first half of the results, more than 40% of the pre-welcomeAmong them, Daan Gene, Fuxiang Pharmaceuticals, Jiu'an Medical and other 6 pharmaceutical enterprises growth of more than 100%In addition, seven companies lost the first moneysix pharmaceutical companies with a growth of more than 100%, including Da'an Gene, Fuxiang Pharmaceuticals, Jiu'an Medical, Fuci Pharmaceuticals, Wahua Pharmaceuticals and Yuheng Pharmaceuticals, Yuheng Pharmaceuticals expects net profit attributable to shareholders of listed companies to be 630 million to 680 million in January-June 2020, a decrease of 171.22 percent to 192.75 percent yoy, and an average net profit growth rate of 9.06 percent for the chemical and pharmaceutical industryThe Company's forecast is based on the following reasons: the increase in the Company's performance over the same period last year was mainly due to the impact of non-recurring profit and loss, which was mainly due to the Company's recognition of the relevant proceeds from the sale of 100% of Aono Pharmaceuticals during the reporting periodExcluding these factors, the company's January-June 2020 results are expected to show a significant decline compared to the same period last yearDaangen issued a results forecast on the evening of April 29, 2020, said that the company's first half of 2020 is expected to net profit of about 303 million yuan to 40 million yuan, an increase of 4.0 times to 6.44 times year-on-yearThe reasons for the change in performance are mainly affected by the outbreak, and the market demand for new coronavirus nucleic acid testing reagents has increased significantlyin the first quarter of this year, Fuxiang Pharmaceuticals' net profit increased by 56.88 percent year-on-year to 83.8094 million yuanThe company said the main reason for the increase was the steady growth in the market demand for the company's main products during the reporting periodFuxiang Pharmaceuticals expects net profit attributable to shareholders of listed companies to be RMB217 million to RMB240 million in the january-June 2020 period, up 90% to 110% YoYJiu'an Medical disclosed its 2020 half-year results forecast that the company is expected to achieve a net profit of 150 million yuan to 200 million yuan in the first half of the year, a year-on-year profitForts Pharmaceuticals expects net profit attributable to shareholders of listed companies to be 801.219 million to 102 million in The First six months of 2020, a year-on-year change of 80.00% to 130.00%, and an average net profit growth rate of 7.18% for the Chinese medicine industryHuaHua Medical expects net profit attributable to shareholders of listed companies to be RMB813.62 million - RMB96.942 million in the first half of 2020, up 160%-210% YoYThe company said that the continued growth of performance, thanks to the continued concentration of advantages in the heart can be comfortable tablets, bone-concincapsules / particles, Hodan tablets / capsules, cerebral blood dredging oral fluid four exclusive health insurance pillar products, full-mode, full terminal sustained strength, sales revenue growthWhile ensuring continued revenue growth, the company significantly increased the efficiency of sales expense spending, sales expense rate significantly reduced, of the 40% pharmaceutical companies, China Resources is expected to make net profit of 860 million to 1.2 billion yuan in the first half of 2020, down 50.07 percent to 30.33 percent year-on-year, and 1.722 billion yuan in the first half of 2019China Resources said that the company's performance significantly declined mainly due to the sale of its 82.89 percent stake in Shenzhen 39 Hospital Co., Ltdin January 2019, which brought about 680 million yuan (after-tax) asset disposal income to the company in 2019, which is non-recurring profit and loss, and is expected to exclude the impact of the above-mentioned non-recurring profit and loss, the company's operating results for the 2020 half year are basically in line with expectationson this, there are industry analysts believe that the pharmaceutical industry has rigid demand attributes, with the domestic hospital outpatient and surgery gradually recovered, non-epidemic products sales will obviously reboundIn addition, the advantages of domestic demand characteristics of the pharmaceutical sector are obvious and will maintain a high degree of attention.